Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Sell
17
PSTV Quote, Financials, Valuation and Earnings
Last price:
$0.75
Seasonality move
:
-10.56%
Day range:
$0.71 - $0.79
52-week range:
$0.24 - $2.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.92x
P/B ratio:
--
Volume:
436.9K
Avg. volume:
32.8M
1-year change:
-59.89%
Market cap:
$12.7M
Revenue:
--
EPS (TTM):
-$2.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics
|
$1.1M | -$0.34 | -- | -54.22% | $9.38 |
|
CATX
Perspective Therapeutics
|
$143.9K | -$0.27 | -- | -35.77% | $14.39 |
|
INFU
InfuSystems Holdings
|
$33.8M | -$0.03 | 7.62% | -40% | $14.13 |
|
RVP
Retractable Technologies
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX
|
$1.1M | -$0.05 | 197.5% | -46.88% | $2.92 |
|
XTNT
Xtant Medical Holdings
|
$30.7M | -$0.02 | 9.96% | -33.33% | $1.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics
|
$0.75 | $9.38 | $12.7M | -- | $0.00 | 0% | 0.92x |
|
CATX
Perspective Therapeutics
|
$1.95 | $14.39 | $144.4M | -- | $0.00 | 0% | 12.62x |
|
INFU
InfuSystems Holdings
|
$4.98 | $14.13 | $104.6M | 49.80x | $0.00 | 0% | 0.80x |
|
RVP
Retractable Technologies
|
$0.68 | -- | $20.4M | -- | $0.00 | 0% | 0.62x |
|
VNRX
VolitionRX
|
$0.49 | $2.92 | $48M | -- | $0.00 | 0% | 34.23x |
|
XTNT
Xtant Medical Holdings
|
$0.41 | $1.75 | $56.6M | -- | $0.00 | 0% | 0.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PSTV
Plus Therapeutics
|
-- | -0.341 | -- | -- |
|
CATX
Perspective Therapeutics
|
-- | -2.375 | -- | -- |
|
INFU
InfuSystems Holdings
|
29.32% | 3.353 | 13.28% | 1.23x |
|
RVP
Retractable Technologies
|
1.55% | 0.051 | 11.72% | 5.80x |
|
VNRX
VolitionRX
|
-28.76% | 0.042 | 8.83% | 0.19x |
|
XTNT
Xtant Medical Holdings
|
44.29% | 0.123 | 55.45% | 0.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics
|
-- | -$3.8M | -- | -- | -- | -$3.7M |
|
CATX
Perspective Therapeutics
|
-- | -$20.9M | -- | -- | -- | -$41.2M |
|
INFU
InfuSystems Holdings
|
$18.2M | $2.6M | 2.82% | 4.33% | 7.76% | $2.8M |
|
RVP
Retractable Technologies
|
-$14.8K | -$5.1M | -16.57% | -16.83% | -18.58% | -$6.5M |
|
VNRX
VolitionRX
|
-- | -$5.8M | -- | -- | -1217.88% | -$5.5M |
|
XTNT
Xtant Medical Holdings
|
$16M | -$1.9M | -21.41% | -35.34% | -6.38% | -$7K |
Plus Therapeutics vs. Competitors
-
Which has Higher Returns PSTV or CATX?
Perspective Therapeutics has a net margin of -- compared to Plus Therapeutics's net margin of --. Plus Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics-- -$0.37 -- CATXPerspective Therapeutics-- -$0.61 -- -
What do Analysts Say About PSTV or CATX?
Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 1150%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that Plus Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Plus Therapeutics is more attractive than Perspective Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics2 0 0 CATXPerspective Therapeutics10 1 0 -
Is PSTV or CATX More Risky?
Plus Therapeutics has a beta of 0.675, which suggesting that the stock is 32.459% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.
-
Which is a Better Dividend Stock PSTV or CATX?
Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or CATX?
Plus Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Plus Therapeutics's net income of -$2.9M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.92x versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics0.92x -- -- -$2.9M CATXPerspective Therapeutics12.62x -- -- -$40.2M
-
Which has Higher Returns PSTV or INFU?
InfuSystems Holdings has a net margin of -- compared to Plus Therapeutics's net margin of 2.76%. Plus Therapeutics's return on equity of -- beat InfuSystems Holdings's return on equity of 4.33%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics-- -$0.37 -- INFUInfuSystems Holdings53.82% $0.04 $81.4M -
What do Analysts Say About PSTV or INFU?
Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 1150%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 183.64%. Given that Plus Therapeutics has higher upside potential than InfuSystems Holdings, analysts believe Plus Therapeutics is more attractive than InfuSystems Holdings.
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics2 0 0 INFUInfuSystems Holdings4 0 0 -
Is PSTV or INFU More Risky?
Plus Therapeutics has a beta of 0.675, which suggesting that the stock is 32.459% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.898, suggesting its more volatile than the S&P 500 by 89.81%.
-
Which is a Better Dividend Stock PSTV or INFU?
Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or INFU?
Plus Therapeutics quarterly revenues are --, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. Plus Therapeutics's net income of -$2.9M is lower than InfuSystems Holdings's net income of $933K. Notably, Plus Therapeutics's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 49.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.92x versus 0.80x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics0.92x -- -- -$2.9M INFUInfuSystems Holdings0.80x 49.80x $33.8M $933K
-
Which has Higher Returns PSTV or RVP?
Retractable Technologies has a net margin of -- compared to Plus Therapeutics's net margin of -18.58%. Plus Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics-- -$0.37 -- RVPRetractable Technologies-0.14% -$0.07 $84.8M -
What do Analysts Say About PSTV or RVP?
Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 1150%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Plus Therapeutics has higher upside potential than Retractable Technologies, analysts believe Plus Therapeutics is more attractive than Retractable Technologies.
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics2 0 0 RVPRetractable Technologies0 0 0 -
Is PSTV or RVP More Risky?
Plus Therapeutics has a beta of 0.675, which suggesting that the stock is 32.459% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.
-
Which is a Better Dividend Stock PSTV or RVP?
Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or RVP?
Plus Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Plus Therapeutics's net income of -$2.9M is lower than Retractable Technologies's net income of -$1.9M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.92x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics0.92x -- -- -$2.9M RVPRetractable Technologies0.62x -- $10.3M -$1.9M
-
Which has Higher Returns PSTV or VNRX?
VolitionRX has a net margin of -- compared to Plus Therapeutics's net margin of -1226.82%. Plus Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics-- -$0.37 -- VNRXVolitionRX-- -$0.07 -$17.8M -
What do Analysts Say About PSTV or VNRX?
Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 1150%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 499.18%. Given that Plus Therapeutics has higher upside potential than VolitionRX, analysts believe Plus Therapeutics is more attractive than VolitionRX.
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics2 0 0 VNRXVolitionRX2 1 0 -
Is PSTV or VNRX More Risky?
Plus Therapeutics has a beta of 0.675, which suggesting that the stock is 32.459% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.
-
Which is a Better Dividend Stock PSTV or VNRX?
Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or VNRX?
Plus Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Plus Therapeutics's net income of -$2.9M is higher than VolitionRX's net income of -$5.8M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.92x versus 34.23x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics0.92x -- -- -$2.9M VNRXVolitionRX34.23x -- $474.5K -$5.8M
-
Which has Higher Returns PSTV or XTNT?
Xtant Medical Holdings has a net margin of -- compared to Plus Therapeutics's net margin of -10.04%. Plus Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics-- -$0.37 -- XTNTXtant Medical Holdings50.85% -$0.02 $77.1M -
What do Analysts Say About PSTV or XTNT?
Plus Therapeutics has a consensus price target of $9.38, signalling upside risk potential of 1150%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 329.98%. Given that Plus Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Plus Therapeutics is more attractive than Xtant Medical Holdings.
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics2 0 0 XTNTXtant Medical Holdings2 0 0 -
Is PSTV or XTNT More Risky?
Plus Therapeutics has a beta of 0.675, which suggesting that the stock is 32.459% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.
-
Which is a Better Dividend Stock PSTV or XTNT?
Plus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or XTNT?
Plus Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Plus Therapeutics's net income of -$2.9M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Plus Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics is 0.92x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics0.92x -- -- -$2.9M XTNTXtant Medical Holdings0.46x -- $31.5M -$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
